News
Press Releases
TSC Alliance and Apertura Gene Therapy Complete Preclinical Pilot Study Evaluating AAV Gene Therapy Approach Designed for TSC1
AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid
Apertura Gene Therapy and Scientists from the Broad Institute to Share Data on TfR1 CapX™, a Novel Capsid Targeting the Central Nervous System (CNS), at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases
Finding Hope for Frizzle (FRRS1L) and Apertura Gene Therapy Announce License Agreement for the Development of a Gene Therapy Using TfR1 CapX, an AAV Capsid Designed to Target the Central Nervous System
Apertura Gene Therapy Launches Open Aperture, a Material Transfer Agreement Program to Facilitate Non-Commercial Access to TfR1 CapX for Academic Researchers
Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments
Apertura Gene Therapy Showcases the Progress of its Novel Human Transferrin Receptor AAV Capsid, TfR1 CapX, and Preclinical Programs for Tuberous Sclerosis Complex (TSC) at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
April 30, 2025
Apertura Gene Therapy and Rett Syndrome Research Trust Collaborate to Pioneer Advanced Genetic Medicines for Rett Syndrome Using TfR1-Targeted AAV Capsid
February 28, 2025
Apertura Gene Therapy Supports the Broad Institute in Development of Gene Therapy for Prion Disease Using Engineered AAV Capsid Targeting TfR1 for CNS Delivery
September 24, 2024
Apertura Gene Therapy to Present at Chardan’s 8th Annual Genetic Medicines Conference
May 10, 2024
Apertura Gene Therapy Showcases Advancements in Capsid Engineering Platform in Presentations at ASGCT Annual Meeting
Apertura Gene Therapy Unveils Novel Engineered AAV Capsids Targeting Human Transferrin Receptor 1 for Neurological Gene Therapy Delivery
Apertura Announces Fit4Function AAV Capsid Engineering Platform and In Vivo Proof-of-Concept Data to Be Presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Apertura Gene Therapy Launches with $67M Series A Financing from Deerfield and an Innovative Technology Platform to Develop Genetic Medicines
